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Background: This study investigated the effects on 24-h lung function and lung volume of a once-daily
ﬁxed-dose combination (FDC) of the long-acting muscarinic antagonist tiotropium and the long-acting
b2-agonist olodaterol in patients with chronic obstructive pulmonary disease.
Methods: This was a randomised, double-blind, placebo-controlled, Phase III trial with an incomplete
crossover design. Patients received four of the following six treatment options for 6 weeks each: placebo,
olodaterol 5 mg, tiotropium 2.5 mg, tiotropium 5 mg, tiotropium þ olodaterol FDC 2.5/5 mg and
tiotropium þ olodaterol FDC 5/5 mg, all delivered via the Respimat® inhaler. The primary end point was
forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 24 h (AUC0e24) response after
6 weeks of treatment; key secondary end points were FEV1 AUC from 0 to 12 h and AUC from 12 to 24 h,
and further end points included lung-volume parameters measured using body plethysmography (subset
of patients), measures of peak and trough FEV1, and incidence of adverse events.
Results: A signiﬁcant improvement in FEV1 AUC0e24 response was observed with tiotropium þ olodaterol
5/5 mg and 2.5/5 mg versus placebo and monotherapies after 6 weeks of treatment; mean response with
tiotropium þ olodaterol 5/5 mg versus placebo was 0.280 L (p < 0.0001). Differences to monotherapies
with tiotropium þ olodaterol 5/5 mg were 0.115 L versus olodaterol 5 mg, 0.127 L versus tiotropium 2.5 mg
and 0.110 L versus tiotropium 5 mg (p < 0.0001 for all comparisons). Secondary end points supported
these data. No safety concerns were identiﬁed.
Conclusions: Overall, this study demonstrated improvements in lung function over 24 h with an FDC of
tiotropium þ olodaterol over tiotropium or olodaterol alone, with no observed difference in tolerability.
ClinicalTrials.gov number: NCT01559116.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).m 0 to 12 h; AUC0e24, area
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Ltd. This is an open access article u1. Introduction
Tiotropium is an established once-daily long-acting muscarinic
antagonist (LAMA) that is effective at improving lung function and
patient-reported outcomes in chronic obstructive pulmonary dis-
ease (COPD) [1e6]. Olodaterol is a novel once-daily long-acting b2-
agonist (LABA) that is highly selective with nearly full intrinsic
activity at b2 receptors [7,8]. Phase III trials have demonstrated that
olodaterol is effective at improving lung function over 24 h in pa-
tients with COPD [9e12] and, importantly, also provides improve-
ments in patient-reported symptoms [11].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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guidelines recognise that combining bronchodilators with different
mechanisms may increase the degree of bronchodilation for
equivalent or lesser side effects than a single bronchodilator [13].
The complementary pharmacological proﬁles of tiotropium and
olodaterol make them a suitable combination and data from pre-
clinical studies support their combination [14]. Two 4-week
Phase II studies demonstrated greater improvements in forced
expiratory volume in 1 s (FEV1) with a once-daily ﬁxed-dose
combination (FDC) of tiotropium and olodaterol than either mon-
ocomponent [15,16]. These studies also explored the optimal dose
for the combination and tiotropium þ olodaterol FDC 2.5/5 mg and
5/5 mg were selected for further investigation in Phase III studies.
While other pivotal Phase III trials have investigated the effects
of tiotropium þ olodaterol FDC on FEV1 at trough and up to 3 h
post-dose, this placebo-controlled trial was designed to provide
rigorous spirometric testing over the 24-h interval (for both FEV1
and forced vital capacity [FVC]), and body plethysmography mea-
surements at peak and trough to place both the lung function and
volume effect sizes into context.
Although FEV1 is a standard measure of lung function in COPD
trials, lung volumes may be more closely associated with patient-
reported outcomes in COPD [17]. Only a few studies have re-
ported the effect of a LAMA þ LABA combination on lung volumes
(including functional residual capacity [FRC] and residual volume
[RV]) and this study investigated these volumes at peak (2 h 30 min
post-dose) and trough (22 h 30 min post-dose) using body pleth-
ysmography [18].
The objective of this study was to demonstrate the 24-h lung-
function proﬁle and effects on lung volume of
tiotropium þ olodaterol FDC 2.5/5 mg and 5/5 mg compared to
placebo and monocomponents after 6 weeks in patients with
moderate to very severe COPD (GOLD 2e4).
2. Methods
2.1. Study design
This was a double-blind, placebo-controlled, multicentre,
Phase III, incomplete crossover study (NCT01559116; 1237.20,
VIVACITO) inwhich patients were randomised to receive four of the
following six treatment options for 6 weeks each, with a 3-week
washout period between treatments: placebo, olodaterol 5 mg,
tiotropium 2.5 mg, tiotropium 5 mg, tiotropium þ olodaterol FDC
2.5/5 mg, tiotropium þ olodaterol FDC 5/5 mg, all delivered via the
Respimat® inhaler (Fig. 1). Detailed written instructions and
training on using the Respimat® inhaler were provided at
screening, and instructions were repeated at the start of each
treatment period.
Following an initial screening visit, patients entered a 2e6-week
baseline period to ensure clinical stability prior to randomisation. A
follow-up visit took place 3 weeks after the last dose of study
medication in the last treatment period. Patients who discontinued
during a treatment period were permitted to continue into their
next treatment period.
2.2. Patients
Patients with COPD aged 40 years with a smoking history of
10 pack-years and relatively stable airway obstruction with a
post-bronchodilator FEV1 <80% of predicted normal (in German
sites only, FEV1 30%) and FEV1/FVC <70% of predicted normal
were included. Exclusion criteria included a history of asthma or
signiﬁcant disease other than COPD, unstable or life-threatening
cardiac arrhythmia, hospitalisation for heart failure within thepast year, a history of myocardial infarction within 1 year of
screening or a history of life-threatening pulmonary obstruction.
Full inclusion and exclusion criteria are provided in Supplementary
Table S1.
Patients were permitted to continue on inhaled corticosteroids
during treatment periods (if taken as maintenance treatment at
study entry) but not anticholinergics or LABAs. During the
screening and washout periods, short-acting anticholinergics were
permitted but had to be stopped 8 h before pulmonary function test
at the ﬁrst visit of the next treatment period. LAMAs and LABAs
were not permitted during washout or screening periods. Open-
label salbutamol was provided to patients as rescue medication
to be used at baseline and during screening, treatment, washout
and follow-up periods.
2.3. Study outcomes
The primary end point was FEV1 area under the curve from 0 to
24 h (AUC0e24) response (change from patient baseline [deﬁned as
average of period baseline values]) and the key secondary end
points were FEV1 area under the curve from 0 to 12 h (AUC0e12)
response and FEV1 area under the curve from 12 to 24 h (AUC12e24)
response. Secondary end points included the maximum FEV1 value
obtained in the ﬁrst 3 h after dosing (peak0e3 FEV1) and trough
FEV1 response, and FVC AUC0e24, FVC AUC0e12 and FVC AUC12e24
responses. Additionally, improvements in FRC and RV were deter-
mined using body plethysmography in a subset of patients
(n ¼ 143) who were measured at baseline and Week 6.
2.4. Assessments
Pulmonary function tests were performed at screening, on Day 1
of each treatment phase (30 min pre-dose and at 30 min, 1, 2 and
3 h post-dose) and at Week 6 of each treatment phase (30 min pre-
dose and at 30min,1, 2, 3, 4, 6, 8,10,12, 22, 23 and 23 h 50min post-
dose). Spirometric tests were performed in triplicate, and the
highest FEV1 and FVC were recorded as per American Thoracic
Society/European Respiratory Society guidelines.
Body plethysmography tests were performed on a subset of
patients at screening and Day 1 (1 h pre-dose treatment baseline)
and Week 6 of each treatment period (2 h 30 min and 22 h 30 min
post-dose). The body plethysmography procedures were per-
formed as ‘linked’ manoeuvres, without the patient coming off the
mouthpiece in between, as recommended by American Thoracic
Society/European Respiratory Society guidelines [19]. Once a quiet
tidal volume breathing pattern was conﬁrmed (to ensure a stable
end-expiratory lung volume), the shutter was closed at end expi-
ratory lung volume and the patient panted with hands over cheeks.
After opening of the shutter, the patient returned to quiet tidal
breathing and then completed an expiratory reserve volume
manoeuvre to RV, followed by a slow inspiratory vital capacity
manoeuvre to total lung capacity. At least three technically
acceptable FRC values had to be obtained, differing by 5%. If the
deviation between values was higher, then the manoeuvre was
repeated until this repeatability was achieved to a maximum of six
times. After six times, the mean FRC was considered acceptable
even if it did not meet the repeatability criteria.
RV was calculated as mean FRC minus mean expiratory reserve
volume. Total lung capacity was calculated as RV plus the largest
technically acceptable inspiratory vital capacity measure. Inspira-
tory capacity was calculated for each individual effort as the dif-
ference between each inspiratory vital capacity and each end
respiratory volume. At least three efforts were performed and if the
individual inspiratory capacity values were not within ±6% of the
mean, additional measures were performed to a maximum of six.
Fig. 1. Trial design. O, olodaterol; T, tiotropium; FDC, ﬁxed-dose combination.
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point for each patient was used for analysis.
All adverse events were recorded, and 12-lead electrocardio-
gram was performed at screening and at 40 min pre-dose and
50 min post-dose on Day 1 and Week 6 of all treatment periods.
Vital signs (pulse rate and blood pressure) were measured prior to
pulmonary function tests on Day 1 and Week 6 of each treatment
period, 30 min before and 50 min, 2 and 3 h after study drug
administration. After 3 weeks of each treatment, patients were
contacted by telephone to report adverse events and changes in
concomitant medicines.
2.5. Statistical analysis
To detect a difference between treatments of 60 mL in FEV1
AUC0e24 with 90% power, including an adjustment for the incom-
plete crossover design and assuming a standard deviation of
190 mL (based on previous studies), 180 patients were required to
complete the trial. An additional 36 were added to allow for drop-
outs, resulting in a required sample size of 216 patients.
The full analysis set was deﬁned as any patient who had taken at
least one dose of studymedication and had any period baseline and
any evaluable post-dose data for the primary end point at the 6-
week time point. This was used for all analyses presented here.
The primary end point, key secondary end points and all other
continuous secondary end points were analysed using a restricted
maximum likelihood-based mixed effects model with repeated
measures that included treatment and period as ﬁxed effects, pa-
tient as a random effect, and period baseline and patient baseline as
covariates. Patient baseline was calculated as the mean of all of the
patient's period baseline values. Hypotheses were tested in a hi-
erarchical order based on adjusted means, with each hypothesis
considered conﬁrmatory only if all of the previous hypotheses were
successful (Supplementary Fig. S1).
3. Results
3.1. Patient disposition and baseline characteristics
Overall, 259 patients were enrolled in the study from 29 centres
in seven countries (Belgium, Canada, Denmark, Germany, Hungary,
The Netherlands and the USA), and 219 were randomised into thetrial and treated (Fig. 2). The discontinuation rate in each treatment
period ranged from 0.7% (with tiotropium þ olodaterol FDC 2.5/
5 mg and FDC 5/5 mg) to 5.8% (with placebo) (Fig. 2).
Patient demographics and baseline characteristics are shown in
Table 1; the majority of patients had GOLD 2 (63.5%) or 3 (34.2%)
COPD, with only ﬁve patients (2.3%) having GOLD 4. Most patients
(83.1%) were taking pulmonary medications at baseline and also
had concomitant diagnoses (95.4%); the most common were
vascular disorders (Table 1). Baseline body plethysmography data
are shown in Supplementary Table S2.
3.2. Efﬁcacy
The 24-h FEV1 time proﬁles showed a consistent improvement
in FEV1 with all active treatments compared to placebo after
6 weeks of treatment (Fig. 3). The tiotropium þ olodaterol FDCs
demonstrated a greater improvement in FEV1 over 24 h than the
monotherapies (Fig. 3). This is quantiﬁed by the signiﬁcantly
greater responses in FEV1 AUC0e24 with tiotropium þ olodaterol
FDCs versus placebo and monotherapies; improvements in lung
function from baseline were 0.241 and 0.244 L with
tiotropium þ olodaterol 2.5/5 mg and 5/5 mg, respectively, and
ranged between 0.117 and 0.133 L for monotherapies (Table 2).
Similarly, FEV1 AUC0e12 and FEV1 AUC12e24 responses were
consistently greater with the tiotropium þ olodaterol FDCs versus
placebo and monotherapies (Table 2); FEV1 AUC0e12 responses
were 0.310 and 0.305 L with tiotropium þ olodaterol 2.5/5 mg and
5/5 mg, respectively, and 0.171e0.186 L with monotherapies. FEV1
AUC12e24 responses were 0.172 and 0.182 L with
tiotropium þ olodaterol 2.5/5 mg and tiotropium þ olodaterol
5/5 mg, respectively, and between 0.062 and 0.081 L with mono-
therapies. Differences between treatments are shown in Table 3;
there were no signiﬁcant differences between
tiotropium þ olodaterol 2.5/5 mg and 5/5 mg in any of these end
points.
As with the FEV1 time proﬁles, FVC 24-h time proﬁles also
demonstrated improvement with tiotropium þ olodaterol FDCs
versus monotherapies and placebo after 6 weeks of treatment
(Supplementary Fig. S2). FVC AUC0e24 responses are shown in
Supplementary Table S3.
Table 4 shows the peak0e3 FEV1 and trough FEV1 responses at
6 weeks; all treatments showed signiﬁcant improvements versus
Fig. 2. Patient disposition. O, olodaterol; T, tiotropium; FDC, ﬁxed-dose combination.
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monotherapies (p < 0.0001 for all comparisons).
FRC was measured using body plethysmography in a subset of
143 patients after 6 weeks of treatment. The
tiotropium þ olodaterol FDCs both provided signiﬁcantly greater
improvements at 2 h 30min post-dose than placebo (p < 0.0001) orTable 1
Baseline demographics and patient characteristics.
Male, n (%)
Mean (SD) age, years
Smoking status, n (%)
Ex-smoker
Current smoker
Pre-bronchodilator mean (SD) FEV1, L
Post-bronchodilator
Mean (SD) FEV1, L
Mean (SD) % predicted normal FEV1
Mean (SD) FEV1/FVC, %
Mean (SD) change from pre- to post-bronchodilator FE
Mean (SD) % change from pre- to post-bronchodilator F
GOLD, n (%)
2
3
4
Most common concomitant diagnoses, n (%)
Vascular disorders
Metabolism and nutrition disorders
Musculoskeletal and connective tissue disorders
Surgical and medical procedures
Baseline pulmonary medication (>1% of patients), n (%)
SAMAa
LAMAb
LABAb
SABAc
Mucolytics
ICS
Xanthines
SD, standard deviation; FEV1, forced expiratory volume in
for chronic Obstructive Lung Disease; SAMA, short-acting
antagonist; LABA, long-acting b2-agonist; SABA, short-act
a Not permitted during treatment periods but allowed
b Not permitted during treatment, screening or washou
c Provided for rescue medication use to all patients thrany of the monotherapies (tiotropium þ olodaterol 2.5/5 mg versus
monotherapies, p < 0.0001ep ¼ 0.007; tiotropium þ olodaterol 5/
5 mg versus monotherapies, p < 0.0001ep ¼ 0.044) (Fig. 4). The
changes from baseline at 2 h 30 min post-dose were 0.052 L with
placebo, 0.435, 0.279 and 0.431 with olodaterol 5 mg, tio-
tropium 2.5 mg and tiotropium 5 mg, respectively, and 0.587 andPatients (n ¼ 219)
129 (58.9)
61.1 (7.7)
82 (37.4)
137 (62.6)
1.361 (0.471)
1.553 (0.487)
54.0 (13.0)
48.0 (10.9)
V1, L 0.193 (0.151)
EV1 15.9 (12.8)
139 (63.5)
75 (34.2)
5 (2.3)
125 (57.1)
118 (53.9)
114 (52.1)
88 (40.2)
17 (7.8)
88 (40.2)
99 (45.2)
133 (60.7)
10 (4.6)
90 (41.1)
8 (3.7)
1 s; FVC, forced vital capacity; GOLD, Global initiative
muscarinic antagonist; LAMA, long-acting muscarinic
ing b-agonist; ICS, inhaled corticosteroid.
during screening and washout periods.
t periods.
oughout the study.
Fig. 3. Adjusted mean 24-h FEV1 proﬁle after 6 weeks of treatment (full analysis set).
FEV1, forced expiratory volume in 1 s; T, tiotropium; O, olodaterol; FDC, ﬁxed-dose
combination.
Table 3
Adjusted mean FEV1 results after 6 weeks, differences between treatments (full
analysis set).
End point Treatment Treatment differences
Mean (SE), L p value 95% CI
FEV1 AUC0e24 TþO 5/5 mg vs:
Placebo 0.280 (0.014) <0.0001 0.252, 0.309
O 5 mg 0.115 (0.014) <0.0001 0.087, 0.143
T 2.5 mg 0.127 (0.014) <0.0001 0.099, 0.155
T 5 mg 0.110 (0.014) <0.0001 0.082, 0.139
TþO 2.5/5 mg 0.003 (0.014) 0.8238 0.025, 0.031
TþO 2.5/5 mg vs:
Placebo 0.277 (0.015) <0.0001 0.249, 0.306
O 5 mg 0.111 (0.014) <0.0001 0.083, 0.140
T 2.5 mg 0.124 (0.014) <0.0001 0.096, 0.152
T 5 mg 0.107 (0.014) <0.0001 0.079, 0.136
FEV1 AUC0e12 TþO 5/5 mg vs:
Placebo 0.319 (0.015) <0.0001 0.289, 0.349
O 5 mg 0.126 (0.015) <0.0001 0.096, 0.156
T 2.5 mg 0.134 (0.015) <0.0001 0.104, 0.164
T 5 mg 0.119 (0.015) <0.0001 0.089, 0.149
TþO 2.5/5 mg 0.005 (0.015) 0.7558 0.035, 0.025
TþO 2.5/5 mg vs:
Placebo 0.323 (0.015) <0.0001 0.293, 0.354
O 5 mg 0.131 (0.015) <0.0001 0.101, 0.161
T 2.5 mg 0.139 (0.015) <0.0001 0.109, 0.169
T 5 mg 0.124 (0.015) <0.0001 0.093, 0.154
FEV1 AUC12e24 TþO 5/5 mg vs:
Placebo 0.243 (0.015) <0.0001 0.212, 0.273
O 5 mg 0.103 (0.015) <0.0001 0.074, 0.133
T 2.5 mg 0.120 (0.015) <0.0001 0.090, 0.150
T 5 mg 0.102 (0.015) <0.0001 0.072, 0.132
TþO 2.5/5 mg 0.011 (0.015) 0.4794 0.019, 0.041
TþO 2.5/5 mg vs:
Placebo 0.232 (0.015) <0.0001 0.201, 0.262
O 5 mg 0.093 (0.015) <0.0001 0.063, 0.123
T 2.5 mg 0.110 (0.015) <0.0001 0.080, 0.140
T 5 mg 0.091 (0.015) <0.0001 0.061, 0.121
n ¼ 132 (placebo); n ¼ 136 (O 5 mg); n ¼ 136 (T 2.5 mg); n ¼ 135 (T 5 mg); n ¼ 135
(TþO 2.5/5 mg); n ¼ 138 (TþO 5/5 mg).
FEV1, forced expiratory volume in 1 s; SE, standard error; CI, conﬁdence interval;
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tively (Fig. 4). At 22 h 30 min post-dose, tiotropium þ olodaterol 5/
5 mg provided signiﬁcantly greater improvements than placebo
(p < 0.0001) and monotherapies (versus olodaterol 5 mg, p ¼ 0.030;
tiotropium 2.5 mg, p ¼ 0.017; tiotropium 5 mg, p ¼ 0.003), and
tiotropium þ olodaterol 2.5/5 mg separated from placebo
(p ¼ 0.0004) and tiotropium 5 mg (p ¼ 0.039) (Fig. 4).
There were also signiﬁcant improvements in RV response with
the FDCs versus placebo and monotherapies at 2 h 30 min and 22 h
30 min post-dose (versus placebo, p < 0.0001; versus mono-
therapies, p < 0.05) (Fig. 4).
All treatments increased inspiratory capacity compared to
placebo at 2 h 30 min and 22 h 30 min post-dose, and
tiotropium þ olodaterol 5/5 mg increased it compared to all
monotherapies at 2 h 30 min post-dose. Inspiratory capacity and
total lung capacity results are provided in Supplementary
Table S4.AUC0e24, area under the curve from 0 to 24 h; T, tiotropium; O, olodaterol; AUC0e12,
area under the curve from 0 to 12 h; AUC12e24, area under the curve from 12 to 24 h.3.3. Safety
Incidence of adverse events was similar between treatment
groups, with no difference between tiotropium þ olodaterol FDC
2.5/5 mg and FDC 5/5 mg and the monotherapies or placebo
(Supplementary Table S5). The most common individual adverse
events were nasopharyngitis, with incidences between 6.5% and
10.1%, and COPD worsening, with incidences between 5.1% and
12.3% (Supplementary Table S5).
Incidences of serious adverse events with each treatment were
2.9% with placebo, 5.8% with olodaterol 5 mg, 3.6% with tiotropium
2.5 mg, 2.2%with tiotropium 5 mg, 2.9%with tiotropiumþ olodaterol
FDC 2.5/5 mg and 0.7% with tiotropium þ olodaterol FDC 5/5 mg. NoTable 2
Adjusted mean FEV1 AUC responses after 6 weeks of treatment (full analysis set).
Treatment Patients, n FEV1 AUC0e24 mean (SE) response, L F
Placebo 132 0.037 (0.014) 
O 5 mg 136 0.129 (0.013)
T 2.5 mg 136 0.117 (0.013)
T 5 mg 135 0.133 (0.014)
TþO 2.5/5 mg 135 0.241 (0.014)
TþO 5/5 mg 138 0.244 (0.013)
FEV1, forced expiratory volume in 1 s; AUC0e24, area under the curve from 0 to 24 h; SE, st
curve from 12 to 24 h; O, olodaterol; T, tiotropium.safety concerns were detected in vital signs (pulse rate or blood
pressure).4. Discussion
4.1. Key ﬁndings
This study demonstrated improvements in the 24-h lung func-
tion proﬁle for an FDC of tiotropium þ olodaterol on dynamic and
static lung volumes. Both tiotropium þ olodaterol FDC doses
showed a clear and consistent improvement in FEV1 over the fullEV1 AUC0e12 mean (SE) response, L FEV1 AUC12e24 mean (SE) response, L
0.013 (0.015) 0.060 (0.014)
0.179 (0.015) 0.079 (0.013)
0.171 (0.015) 0.062 (0.013)
0.186 (0.015) 0.081 (0.014)
0.310 (0.015) 0.172 (0.014)
0.305 (0.015) 0.182 (0.013)
andard error; AUC0e12, area under the curve from 0 to 12 h; AUC12e24, area under the
Table 4
Adjusted mean peak0e3 FEV1 and trough FEV1 responses at 6 weeks (full analysis
set).
n Peak0e3 FEV1, L (SE) n Trough FEV1, L (SE)
Placebo 135 0.072 (0.017) 132 0.006 (0.015)
O 5 mg 138 0.291 (0.016)a 136 0.109 (0.015)a
T 2.5 mg 136 0.290 (0.016)a 136 0.095 (0.015)a
T 5 mg 137 0.300 (0.016)a 135 0.122 (0.015)a
TþO 2.5/5 mg 135 0.422 (0.016)a,b 135 0.196 (0.015)a,b
TþO 5/5 mg 138 0.411 (0.016)a,b 138 0.201 (0.015)a,b
Common patient baseline mean (SE), 1.301 L (0.030).
Peak0e3, maximum value obtained in the ﬁrst 3 h after dosing; FEV1, forced expi-
ratory volume in 1 s; SE, standard error; O, olodaterol; T, tiotropium.
a p < 0.0001 vs placebo.
b p < 0.0001 vs monotherapies.
K.-M. Beeh et al. / Pulmonary Pharmacology & Therapeutics 32 (2015) 53e595824-h period compared to placebo and monotherapies, as expected
from combining a LAMA and a LABA [20]. The improvement in
trough FEV1 with tiotropium þ olodaterol FDCs versus placebo
(0.207 L with tiotropium þ olodaterol 5/5 mg) was greater than is
considered clinically important [21]. Both tiotropium þ olodaterol
FDC doses also demonstrated a greater increase in FEV1 AUC0e24
than tiotropium 5 mg alone, a well-established and widely used
once-daily LAMA. These improvements were accompanied by a
tolerability proﬁle similar to tiotropium 5 mg, olodaterol and pla-
cebo. In this study, no differences in spirometric variables were
observed in effect size between the two FDC doses, although in
longer-term studies differences have been observed with some end
points [22]. This difference may be due to the shorter-term nature
of this study.
The improvements in FEV1 with the FDCs versusmonotherapies
and placebo were also seen with FVC over the 24-h period. The
body plethysmography substudy provided evidence for an incre-
mental beneﬁt of the tiotropiumþ olodaterol combination in terms
of hyperinﬂation, as greater reductions in FRC were seen with
combined tiotropiumþ olodaterol compared to the monotherapies
at 2 h 30 min post-dose. Trapped air volume, as measured by RV,
was also reduced to a greater extent with the combined treatments
compared to the monotherapies at peak and trough.4.2. Possible mechanisms
When taken together, the data suggest that
tiotropium þ olodaterol FDC reduces airﬂow limitation over 24 h,
which improves lung emptying at the end of tidal breathing and
reduces hyperinﬂation (FRC), as well as reducing the trapped airFig. 4. Adjusted mean FRC (a) and RV (b) responses at 6 weeks ± SE, measured by body p
**p < 0.0001 versus placebo; yp < 0.05 versus all monotherapies; yyp < 0.01 versus all mon
O, olodaterol; T, tiotropium; FDC, ﬁxed-dose combination.volume (RV). Our results suggest that the positive effects on lung
volume, which are known to correlate better with patient-reported
improvements than FEV1, are maintained over the full 24-h dosing
interval.
By targeting both routes to airway smooth muscle relaxation,
b2-agonism and muscarinic antagonism, the combination of a
LAMA with a LABA achieves greater bronchodilation than either
drug alone, exceeding clinically important differences for FEV1
versus placebo andmonocomponents. Complementary interactions
between these two pathways may also play a role in the greater
improvements demonstrated in this study with dual therapy versus
monotherapy [23].
4.3. Comparison with relevant ﬁndings from other published
studies
The effects of tiotropium þ olodaterol FDC on 24-h lung func-
tion, as demonstrated here by rigorous pulmonary function testing
over the full dosing interval, are consistent with the effects on
trough FEV1 from Phase II tiotropium þ olodaterol data [15,16] and
on both trough and FEV1 area under the curve from 0 to 3 h from
Phase III long-term study results [22]. They are also consistent with
the results of adding twice-daily b2-agonists such as formoterol and
salmeterol to tiotropium [23].
Similar lung function and symptomatic beneﬁts versus their
respective monocomponents have also been reported with other
LAMA þ LABA combinations: umeclidinium þ vilanterol,
indacaterol þ glycopyrronium and glycopyrrolate þ formoterol,
reviewed by Tashkin and Ferguson [23] and Bateman et al. [20]. An
indacaterol þ glycopyrronium study used body plethysmography
to investigate lung-volume measures after 3 weeks of treatment at
up to 1 h post-dose and found improvements versus placebo [18], so
the data presented here at 6 weeks, and at a longer period post-
dose, extend these effects. In this study, we also demonstrate an
improvement versus monotherapies as well as versus placebo in
FRC and RV. The improvements versus placebo in FRC are similar to
those previously reported with another LAMAþ LABA combination
[18], although the difference from placebo in post-dose RV is
greater in the present study, and in VIVACITO a signiﬁcant
improvement versus monotherapies is also reported.
4.4. Limitations of the present study
Although no safety concerns were raised in the trial, the short
duration of the study and the crossover design limit the safety in-
formation that can be established from this trial alone. The two 52-lethysmography at 2 h 30 min and 22 h 30 min post-dose. *p < 0.05 versus placebo;
otherapies. FRC, functional residual capacity; RV, residual volume; SE, standard error;
K.-M. Beeh et al. / Pulmonary Pharmacology & Therapeutics 32 (2015) 53e59 59week parallel-group trials that investigated the two FDCs versus
monocomponents also demonstrated a tolerability proﬁle with
tiotropium þ olodaterol similar to monotherapies [22].
Another limitation is that the 24-h proﬁle was calculated using
data from 0 to 12 and 22 to 24 h to allow patients to get a relatively
full night's sleep, so the proﬁle from 12 to 22 h is interpolated.
However, given the linear proﬁle from the peak to 22 h, this is a
reasonable compromise, and the consistency between treatment
groups in diurnal variation suggests that treatment differences are
likely to be consistent in the 12 to 22 h period, as found in a pre-
vious tiotropium study where FEV1 was measured throughout the
night [24]. It is possible, however, that the lowest point in the 24-h
period is not at 22 h but at some point between 12 and 22 h.
4.5. Clinical implications
Overall, this study provides strong evidence for an incremental
beneﬁt in lung function with tiotropium þ olodaterol FDC
compared to placebo or tiotropium or olodaterol alone.
5. Conclusions
Tiotropium þ olodaterol FDC 2.5/5 mg and tiotropium þ olo-
daterol FDC 5/5 mg demonstrated greater improvements in lung-
function proﬁle over 24 h than either tiotropium or olodaterol
alone, with no observed differences in safety.
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